Advancements in the Management of R/R AML: ASH 2024 - Episode 4
Revumenib’s FDA Approval and Clinical Implications
Panelists discuss the FDA approval of revumenib for relapsed/refractory acute leukemia (R/R AML) with KMT2A translocation, reviewing the eligible patient population and the mechanism of action of this menin inhibitor, while exploring key findings from the AUGMENT-101 trial and how this approval may impact treatment approaches in both the R/R and broader AML settings.
Video content above is prompted by the following:
- Provide details of the FDA approval on November 15, 2024, for revumenib in R/R acute leukemia with KMT2A translocation.
- Briefly review the population, and which patients can be treated with this new therapy.
- Briefly discuss the mechanism of action of this menin inhibitor, revumenib.
- Briefly comment on key takeaways from AUGMENT-101 efficacy and safety data that led to FDA approval
- What aspects of revumenib’s efficacy and safety profile stand out compared with other approved agents in AML?
- How does this FDA approval impact your treatment approach for AML overall (including R/R setting)?
Related Content:
